Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endoreg
- Development stage
- Unknown
- Lead developer
- Jagsonpal Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Endoreg is an oral gynaecological medication containing 2mg of dienogest, a synthetic progestin. Developed and marketed by Jagsonpal Pharmaceuticals, it is primarily indicated for the treatment of endometriosis and the management of associated pelvic pain. Dienogest works by suppressing the production of estradiol, thereby inhibiting the excessive growth of endometrial tissue and relieving symptoms. It acts as a selective progesterone receptor agonist with potent endometrial effects but moderate antigonadotropic activity, making it effective for long-term management of endometriosis symptoms.
- Brand names
- Endoreg
- Other names
- dienogest
02
Targets
PR (Progesterone receptor)
Beyond the preview
Go deeper on Endoreg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endoreg.